

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Gao et al.)	GROUP ART UNIT:	1615
)		
SERIAL NO.:	10/633,390)	CONFIRMATION NO.:	2821
)		
EXAMINER:	Hawes)	ATTORNEY DOCKET NO.:	01260/2/US
)		
FILED:	July 31, 2003)		(PC 27637)
TITLE:	PHARMACEUTICAL DOSAGE FORM CAPABLE OF MAINTAINING STABLE DISSOLUTION PROFILE UPON STORAGE			

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 14, 2006

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Office action of June 30, 2006 in the above-identified application, please consider the following remarks.

Claims 1-34 are pending, and are subject to restriction between Group I (claims 1-31 and 34) and Group II (claims 32 and 33).

Applicants elect the invention of Group I, and reserve the right to file one or more divisional applications directed to the non-elected subject matter.

Further to the request under 35 U.S.C. §121, requiring election of species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable, Applicants elect:

1. COX-2 inhibitor: celecoxib, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, which corresponds to a compound of Formula I, as defined in claim 25, wherein A is pyrazolyl; n is 0; R¹ is

phenyl substituted with methyl; R² is amino; R³ is trifluoromethyl; and R⁴ is hydrido;

2. amine agent: tromethamine;
3. excipient: sulfite;
4. sulfite compound: sodium metabisulfite
5. free radical scavenging antioxidant: propyl gallate;
6. sweetener: mannitol;
7. preservative: benzalkonium chloride;
8. surfactant: polysorbate 80;
9. solvent: PEG 400.
10. co-solvent: ethanol.

Applicants submit that the present invention is now in condition for allowance.

Early allowance of all pending claims is respectfully solicited.

Respectfully submitted,



Patricia K. Fitzsimmons
Registration No. 52,894

Pharmacia Corporation
Post Office Box 1027
St. Louis, MO 63006
Telephone: 314.274.1490
Facsimile: 314.274.9095